FR05C0033I2 - R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate - Google Patents

R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate

Info

Publication number
FR05C0033I2
FR05C0033I2 FR05C0033C FR05C0033C FR05C0033I2 FR 05C0033 I2 FR05C0033 I2 FR 05C0033I2 FR 05C0033 C FR05C0033 C FR 05C0033C FR 05C0033 C FR05C0033 C FR 05C0033C FR 05C0033 I2 FR05C0033 I2 FR 05C0033I2
Authority
FR
France
Prior art keywords
esylate
indane
propargyl
mesylate
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR05C0033C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of FR05C0033I1 publication Critical patent/FR05C0033I1/fr
Application granted granted Critical
Publication of FR05C0033I2 publication Critical patent/FR05C0033I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR05C0033C 1993-10-18 2005-08-09 R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate Active FR05C0033I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13951793A 1993-10-18 1993-10-18
PCT/US1994/011567 WO1995011016A1 (en) 1993-10-18 1994-10-12 R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof

Publications (2)

Publication Number Publication Date
FR05C0033I1 FR05C0033I1 (enExample) 2005-09-30
FR05C0033I2 true FR05C0033I2 (fr) 2006-12-29

Family

ID=22487049

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0033C Active FR05C0033I2 (fr) 1993-10-18 2005-08-09 R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate

Country Status (17)

Country Link
EP (1) EP0812190B1 (enExample)
JP (3) JPH09505806A (enExample)
AT (1) ATE284208T1 (enExample)
AU (1) AU1253495A (enExample)
CA (1) CA2174449C (enExample)
DE (2) DE69434178T2 (enExample)
DK (1) DK0812190T3 (enExample)
ES (1) ES2235170T3 (enExample)
FR (1) FR05C0033I2 (enExample)
HU (1) HU226138B1 (enExample)
IL (1) IL111240A (enExample)
LU (1) LU91191I2 (enExample)
MX (1) MXPA94008019A (enExample)
NL (1) NL300205I2 (enExample)
PT (1) PT812190E (enExample)
WO (1) WO1995011016A1 (enExample)
ZA (1) ZA948013B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
HU225986B1 (en) * 1994-01-10 2008-02-28 Teva Pharma Use of 1-aminoindan derivatives for preparing pharmaceutical compns. and 1-aminoindan derivatives
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
EP0808160A1 (en) 1995-02-10 1997-11-26 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
ATE241346T1 (de) * 1995-03-02 2003-06-15 Scherer Technologies Inc R P Arzneimittel enthaltend monoaminooxidase-b-hemmer
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
ATE377585T1 (de) 1996-12-18 2007-11-15 Teva Pharma Aminoindanderivate
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
AU2472499A (en) * 1998-01-27 1999-08-09 Thomas N. Thomas Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
JP2003512426A (ja) 1999-10-27 2003-04-02 テバ ファーマシューティカル インダストリーズ リミティド 双極性気分障害における躁病の治療のための１−アミノインダンの使用。
US7396860B2 (en) * 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
AU2006216696B2 (en) * 2005-02-23 2011-08-18 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
AU2006326642B2 (en) 2005-12-09 2012-05-03 Technion Research And Development Foundation Ltd. Use of low-dose ladostigil for neuroprotection
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US8946300B2 (en) * 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ATE528989T1 (de) 2006-12-14 2011-11-15 Teva Pharma Kristalline feste rasagilin-base
US7547806B2 (en) 2006-12-14 2009-06-16 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
NZ585752A (en) * 2007-12-24 2011-11-25 Cipla Ltd Process for the synthesis of propargylated aminoindan derivatives
EP2271612B1 (en) * 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagiline mesylate particles and process for the preparation thereof
US7781616B2 (en) 2008-05-23 2010-08-24 Medichem, S.A. Method for obtaining an aminoindan mesylate derivative
CN102123980B (zh) * 2008-06-02 2014-05-07 基因里克斯(英国)有限公司 用于制备对映异构纯胺的方法
CN102203053B (zh) * 2008-06-02 2015-11-25 基因里克斯(英国)有限公司 用于制备胺的改进方法
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
EP2328861A2 (en) 2008-07-11 2011-06-08 Synthon BV Polymorphs of rasagiline hydrochloride
WO2010007181A2 (en) * 2008-07-18 2010-01-21 Medichem, S.A. New salt forms of an aminoindan derivative
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
HRP20140845T1 (hr) * 2009-07-09 2014-11-07 Ratiopharm Gmbh Soli rasagilina i farmaceutski pripravci od njih
CN102048717B (zh) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
EP2939669A1 (en) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
WO2011080589A2 (en) 2009-12-30 2011-07-07 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
US9943489B2 (en) * 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
WO2011121607A2 (en) * 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
EP2389927A1 (en) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
CN102464589A (zh) * 2010-11-17 2012-05-23 凯瑞斯德生化(苏州)有限公司 雷沙吉兰、其甲磺酸盐及其中间体的制备方法
EP2663545B1 (en) 2011-01-13 2015-07-01 Nobel Ilaç Sanayii Ve Ticaret A.S. A new method for the synthesis of rasagiline
WO2012116752A1 (en) 2011-03-03 2012-09-07 Synthon Bv Process of resolution of 1-aminoindan
WO2012153349A2 (en) 2011-05-04 2012-11-15 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
EA201490761A1 (ru) * 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
ES2524865T1 (es) 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
EP2764862A1 (en) 2013-02-06 2014-08-13 Galenicum Health S.L. Immediate release tablets of rasagiline hemitartrate
IN2013MU01782A (enExample) * 2013-05-20 2015-06-26 Cadila Healthcare Ltd

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO1995011016A1 (en) 1995-04-27
DE122005000044I1 (de) 2005-12-22
DK0812190T3 (da) 2005-04-11
IL111240A0 (en) 1994-12-29
NL300205I1 (nl) 2005-10-03
DE69434178T2 (de) 2005-12-01
NL300205I2 (nl) 2006-03-01
AU1253495A (en) 1995-05-08
IL111240A (en) 2001-10-31
LU91191I2 (fr) 2005-10-10
ES2235170T3 (es) 2005-07-01
JP2003160481A (ja) 2003-06-03
DE122005000044I2 (de) 2007-09-13
PT812190E (pt) 2005-04-29
HU9601012D0 (en) 1996-06-28
EP0812190B1 (en) 2004-12-08
HUT77934A (hu) 1998-11-30
CA2174449C (en) 2007-01-16
FR05C0033I1 (enExample) 2005-09-30
ATE284208T1 (de) 2004-12-15
CA2174449A1 (en) 1995-04-27
MXPA94008019A (es) 2004-08-10
ZA948013B (en) 1995-05-31
DE69434178D1 (de) 2005-01-13
HU226138B1 (en) 2008-05-28
JP2010018626A (ja) 2010-01-28
EP0812190A4 (en) 1998-03-04
EP0812190A1 (en) 1997-12-17
JPH09505806A (ja) 1997-06-10

Similar Documents

Publication Publication Date Title
FR05C0033I2 (fr) R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate
DE69829866D1 (de) Sklerotische prothese für die behandlung von altersweitsichtigkeit und anderen augenkrankheiten
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
FI970771L (fi) Uusia allergisten sairauksien hoidossa käyttökelpoisia substituoituja piperidiinejä
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
DE59603216D1 (de) Esterquats und ihre Verwendung zur Herstellung von oberflächenaktiven Mitteln, insbesondere zur Haar- und Körperpflege
FI901289A7 (fi) Muistia ja oppimista parantava tai kognitiivisten tai psykoottisten häiriöiden hoidossa käytettävä koostumus, joka sisältää D-sykloseriiniä ja D-alaniinia
FI970859A7 (fi) Metallien käsittelykoostumus ja -prosessi
DE69014030D1 (de) Mittel für die Verhütung und Behandlung von Diarrhöe.
FR2629714B1 (fr) Composition de shampooing transparente, son procede de fabrication et procede l'utilisant pour le traitement des cheveux
EP0832204A4 (en) TREATMENT OF INSULIN RESISTANCE
DE4397173T1 (de) Verbesserter Damenstrumpf und Halter hierfür
EP1469852A4 (en) NITROGEN DONORS FOR THE TREATMENT OF DISEASE AND INJURY
EP1015034A4 (en) CONSTRUCTION AND USE OF A GENE THAT COVERS FOR PATHOGENIC EPITOPES FOR THE TREATMENT OF AUTOIMMUN DISEASES
FI971127A7 (fi) 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollagee nin kypsymis- ja rakentumishäiriöiden hoitamiseen
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
FR2758465B1 (fr) Composition pour le traitement de l'amiante
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FR2781504B1 (fr) Foulon pour le traitement des cuirs, peaux et similaires
DE69520268D1 (de) Behandlung von Legierungen und danach hergestellte Gegenstände
EP0859761A4 (en) 4-AZASTEROIDS FOR TREATING HYPERANDROGEN STATES
EP0687470A3 (en) Compounds for the treatment of metabolic bone diseases
EP0800396A4 (en) TREATMENT OF HYPERANDROGEN STATES
EP0969852A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND FETISH ADDICTION
EP1157694A4 (en) REMEDIES OF THE ERECTIONAL DISORDER